# A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct05582395` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05582395](<https://clinicaltrials.gov/study/NCT05582395>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05582395

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 580 participants.

## Technical summary

Registry record NCT05582395. Randomized; double masking; primary purpose treatment. Start 2022-12-14 (actual); primary completion 2025-03-06 (actual). Results posted on 2026-08-20.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 580 participants (enrolled count; ClinicalTrials.gov record NCT05582395, source copy `cardio:ctgov-nct05582395-2026-09-18`, retrieved 2026-10-31)
- Started: 2022-12-14 (actual) (ClinicalTrials.gov record NCT05582395, source copy `cardio:ctgov-nct05582395-2026-09-18`, retrieved 2026-10-31)
- Primary completion: 2025-03-06 (actual) (ClinicalTrials.gov record NCT05582395, source copy `cardio:ctgov-nct05582395-2026-09-18`, retrieved 2026-10-31)
- Completion: 2025-10-20 (actual) (ClinicalTrials.gov record NCT05582395, source copy `cardio:ctgov-nct05582395-2026-09-18`, retrieved 2026-10-31)
- Results first posted: 2026-08-20 (ClinicalTrials.gov record NCT05582395, source copy `cardio:ctgov-nct05582395-2026-09-18`, retrieved 2026-10-31)
- Countries: United States; Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Hungary; India; Israel; Italy; Japan; Netherlands; Norway; Poland; Portugal; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT05582395, source copy `cardio:ctgov-nct05582395-2026-09-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05582395-2026-09-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- Acronym: ODYSSEY-HCM
- Condition: Cardiomyopathy, Hypertrophic
- Intervention (Drug): Mavacamten
- Intervention (Other): Placebo
- Lead sponsor: Bristol-Myers Squibb
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry intervention name matches this record: Mavacamten (`cardio:mavacamten`)
- Registry lists this organization as the lead sponsor: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (`cardio:pubmed-40888717`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial (`cardio:pubmed-40864018`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 309e235e57ac4abd803db3ddc1921c47911d6169313da4311d1b03003f782d6e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
